GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Monte Rosa Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$10.66+0.92 (+9.45%)

Close on Oct 19, 2026

Market cap: $1.08B
P/E (TTM): –
Dividend yield: –

Monte Rosa Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	124	76	0	–	–	–
Research & Development	142	122	111	85	57	24
General & Administrative	36	35	32	27	16	4.01
Operating Expenses	178	157	143	112	73	28
Operating Income	-54	-81	-143	-112	-73	-28
Other Non-Operating Income	14	11	8.30	3.88	-1.08	-7.87
Asset Impairment Charges	0	0	0	0	0	0
Gain (Loss) on Investments	–	–	-0.13	0	–	–
Gain (Loss) on Sale of Assets	0.06	0	0.02	0.11	0	0
Pretax Income	-40	-70	-135	-109	–	–
Income Tax Expense	-1.10	2.57	0.34	0	–	–
Net Income incl. Noncontrolling Interests	-39	-73	-135	-109	-74	-36
Net Income	-39	-73	-135	-109	-74	-36
EPS (Basic)(per share)	–	–	–	–	-2.96	-23.65
EPS (Diluted)(per share)	–	–	–	–	-2.96	-23.65
Shares Outstanding (Basic, Weighted)(shares)	83	74	51	47	25	1.52
Shares Outstanding (Diluted, Weighted)(shares)	83	74	51	47	25	1.52

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -633.0%
Net margin: -560.8%
Return on equity, FY2025: -16.9%

Financial strength

Current ratio: 10.58
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 151.0%

Valuation

P/E ratio: –
Price to sales: 37.66
Price to book: 2.22
Dividend yield: –